Skip to main content
CNC
NYSE Finance

Centene Reports 2025 GAAP Loss Driven by Impairments, Forecasts Strong Adjusted EPS Rebound for 2026

Analysis by Wiseek.ai
Sentiment info
Positive
Importance info
8
Price
$38.21
Mkt Cap
$19.621B
52W Low
$25.075
52W High
$66.03
Market data snapshot near publication time

summarizeSummary

Centene Corporation announced a GAAP loss for the full year 2025 due to significant goodwill and asset impairments, but provided optimistic 2026 guidance projecting adjusted diluted EPS to be greater than $3.00, a substantial increase from $2.08 in 2025.


check_boxKey Events

  • 2025 Full Year Financial Results

    Reported a GAAP diluted loss per share of $(13.53) and adjusted diluted earnings per share of $2.08 for the full year ended December 31, 2025.

  • Significant Impairment Charges

    The 2025 GAAP loss was primarily driven by a $6.7 billion non-cash goodwill impairment in Q3 2025 and a $513 million impairment related to the divestiture of Magellan Health businesses in Q4 2025.

  • Strong 2026 Adjusted EPS Guidance

    Provided full year 2026 guidance for adjusted diluted earnings per share of greater than $3.00, a significant increase from the $2.08 reported in 2025.

  • Operational Improvement Outlook

    Management expects meaningful margin improvement and renewed adjusted diluted EPS growth in 2026, with anticipated improvements in Health Benefits Ratio (HBR) and Adjusted SG&A expense ratio.


auto_awesomeAnalysis

Centene Corporation announced a challenging financial performance for the full year 2025, reporting a significant GAAP diluted loss per share of $(13.53). This loss was primarily attributable to substantial non-cash impairment charges, including a $6.7 billion goodwill impairment in the third quarter and a $513 million impairment related to the divestiture of Magellan Health businesses in the fourth quarter. Despite these backward-looking challenges, the company provided a strong and optimistic outlook for 2026, projecting adjusted diluted earnings per share to be greater than $3.00. This guidance represents a substantial increase from the $2.08 adjusted diluted EPS reported in 2025, signaling management's confidence in achieving meaningful margin improvement and renewed earnings growth. Investors will likely focus on this forward-looking guidance as a key indicator of the company's operational turnaround and future profitability.

At the time of this filing, CNC was trading at $38.21 on NYSE in the Finance sector, with a market capitalization of approximately $19.6B. The 52-week trading range was $25.08 to $66.03. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed CNC - Latest Insights

CNC
Apr 28, 2026, 6:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
CNC
Apr 27, 2026, 8:08 PM EDT
Filing Type: 8-K
Importance Score:
8
CNC
Apr 27, 2026, 8:07 PM EDT
Filing Type: 10-Q
Importance Score:
8
CNC
Mar 26, 2026, 4:26 PM EDT
Filing Type: DEF 14A
Importance Score:
8
CNC
Mar 10, 2026, 1:11 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
CNC
Mar 09, 2026, 6:20 PM EDT
Filing Type: 8-K
Importance Score:
8
CNC
Feb 17, 2026, 4:31 PM EST
Filing Type: 10-K
Importance Score:
9
CNC
Feb 05, 2026, 8:52 PM EST
Filing Type: 8-K
Importance Score:
8